Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort
Table 1
Comparison of the distribution of clinical and pathologic factors in men selected for bilateral or unilateral versus non-nerve sparing radical prostatectomy.
Clinical factor
Non-nerve sparing (non-NS)
Unilateral nerve sparing (UNS)
Bilateral nerve sparing (BNS)
value comparing non-NS, UNS, and BNS
Median PSA (IQR) (ng/mL)
4.6 [4.0, 10.0]
5.0 [4.0, 6.2]
4.6 [3.5, 6.0]
0.137
Median PPB (IQR) (%)
50.0 [18.2, 70.0]
33.3 [25.0, 50.0]
16.7 [10.0, 25.0]
<0.0001
PSA and PPB category*
Both > median
8 (10.39%)
50 (64.94%)
19 (24.68%)
<0.0001**
PSA > median PPB ≤ Median
1 (1.04%)
30 (31.25%)
65 (67.71%)
<0.0001**
PSA ≤ median PPB > median
5 (6.25%)
49 (61.25%)
26 (32.50%)
<0.0001**
Both ≤ median
5 (4.81%)
22 (21.15%)
77 (74.04%)
<0.0001**
Median age (IQR) (yrs)
60.2 [52.0, 67.2]
61.4 [57.4, 64.9]
57.8 [52.9, 61.9]
<0.0001
AJCC clinical tumor category
<0.0001**
1c
16 (84%)
109 (72%)
170 (91%)
2-3
3 (16%)
42 (28%)
17 (9%)
Biopsy Gleason score
<0.0001**
7 or less
11 (58%)
131 (87%)
187 (100%)
8 to 10
8 (42%)
20 (13%)
0 (0%)
AJCC prostatectomy tumor category
<0.0001**
2
12 (63%)
119 (79%)
174 (93%)
3-4
7 (37%)
32 (21%)
13 (7%)
Prostatectomy Gleason score
<0.0001**
7 or less
13 (68%)
129 (85%)
187 (100%)
8–10
6 (32%)
22 (15%)
0 (0%)
Margin status
<0.0001**
Positive
8 (42%)
18 (12%)
10 (5%)
Negative
11 (58%)
133 (88%)
177 (95%)
PSA: prostate-specific antigen; PPB: percentage of positive prostate biopsies; IQR: interquartile range; AJCC: American Joint Commission on Cancer. *Overall, median PPB = 25%; overall, median PSA = 4.8 ng/mL; overall, 7% had PSA ≥ 10 ng/mL. **Fisher exact test value.
